Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medigene ( (DE:MDG1) ) has provided an announcement.
Medigene AG, a company listed on the Frankfurt Stock Exchange, has announced that the Munich Local Court has initiated insolvency proceedings for its assets and those of its subsidiary, Medigene Immunotherapies GmbH. The court has appointed Mr. Axel W. Bierbach as the insolvency administrator, indicating significant financial distress for the company, which may impact its operations and stakeholders.
The most recent analyst rating on (DE:MDG1) stock is a Buy with a EUR6.00 price target. To see the full list of analyst forecasts on Medigene stock, see the DE:MDG1 Stock Forecast page.
More about Medigene
Average Trading Volume: 15,430
Technical Sentiment Signal: Sell
Current Market Cap: €1.7M
For a thorough assessment of MDG1 stock, go to TipRanks’ Stock Analysis page.